Good Rx Holdings, Inc. GDRX
We take great care to ensure that the data presented and summarized in this overview for GoodRx Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GDRX
View all-
Francisco Partners Management, LP San Francisco, CA70.1MShares$348 Million57.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.91MShares$39.2 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN5.08MShares$25.2 Million0.01% of portfolio
-
Rubric Capital Management LP New York, NY4.68MShares$23.2 Million0.91% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.32MShares$21.4 Million0.02% of portfolio
-
American Century Companies Inc Kansas City, MO4.29MShares$21.3 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$18.9 Million0.02% of portfolio
-
Lakewood Capital Management, LP New York, NY3.72MShares$18.5 Million2.22% of portfolio
-
Silver Lake Group, L.L.C. Menlo Park, CA3.53MShares$17.5 Million0.19% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.99MShares$14.8 Million0.03% of portfolio
Latest Institutional Activity in GDRX
Top Purchases
Top Sells
About GDRX
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
Insider Transactions at GDRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 21
2025
|
Scott Wagner Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,741
+4.4%
|
-
|
|
Jan 15
2025
|
Romin Nabiey Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,071
-1.15%
|
$4,284
$4.15 P/Share
|
|
Jan 15
2025
|
Romin Nabiey Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,606
+2.72%
|
-
|
|
Jan 08
2025
|
Karsten Voermann Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,035
-7.4%
|
$116,140
$4.41 P/Share
|
|
Jan 08
2025
|
Karsten Voermann Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
89,292
+18.53%
|
-
|
|
Jan 01
2025
|
Ronald E Bruehlman Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,653
+24.81%
|
-
|
|
Jan 01
2025
|
Douglas Joseph Hirsch Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,392
+3.98%
|
-
|
|
Dec 21
2024
|
Kelly J. Kennedy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,150
+30.0%
|
$92,600
$4.44 P/Share
|
|
Dec 08
2024
|
Scott Wagner Director |
SELL
Payment of exercise price or tax liability
|
Direct |
35,776
-11.01%
|
$143,104
$4.91 P/Share
|
|
Dec 08
2024
|
Scott Wagner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
70,591
+17.85%
|
-
|
|
Dec 08
2024
|
Romin Nabiey Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,437
-2.4%
|
$17,748
$4.91 P/Share
|
|
Dec 08
2024
|
Romin Nabiey Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,432
+6.15%
|
-
|
|
Dec 08
2024
|
Karsten Voermann Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,659
-7.52%
|
$98,636
$4.91 P/Share
|
|
Dec 08
2024
|
Karsten Voermann Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
54,064
+14.15%
|
-
|
|
Nov 08
2024
|
Romin Nabiey Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,519
-5.2%
|
$22,595
$5.04 P/Share
|
|
Nov 08
2024
|
Romin Nabiey Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,663
+12.71%
|
-
|
|
Nov 08
2024
|
Scott Wagner Director |
SELL
Payment of exercise price or tax liability
|
Direct |
35,777
-12.33%
|
$178,885
$5.04 P/Share
|
|
Nov 08
2024
|
Scott Wagner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
70,592
+19.57%
|
-
|
|
Nov 08
2024
|
Ronald E Bruehlman Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,631
+49.33%
|
-
|
|
Oct 26
2024
|
Douglas Joseph Hirsch Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,394
+6.42%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 207K shares |
|---|---|
| Exercise of conversion of derivative security | 989K shares |
| Conversion of derivative security | 25.7M shares |
| Bona fide gift | 15.8M shares |
| Bona fide gift | 15.8M shares |
|---|---|
| Payment of exercise price or tax liability | 427K shares |
| Open market or private sale | 89.7K shares |
| Sale (or disposition) back to the issuer | 20.9M shares |
| Other acquisition or disposition | 3.99M shares |